World s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for

Size: px
Start display at page:

Download "World s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for"

Transcription

1

2 Table of Contents SCOPE AND METHODOLOGY... 8 Market Definition... 8 Market Scope... 8 Market Stakeholders... 9 Research Methodology Secondary and Primary Research Methodology Market Size Estimation Methodology Market Forecast Methodology Assumptions Years Considered for the Study Currency EXECUTIVE SUMMARY Introduction BACKGROUND ipsc RESEARCH About ipscs Importance of ipscs in Modern Medical Science Evolution of ipsc Research and Application Scientific Discoveries and Progress Since Discovery of ipscs Potential Future Use of ipscs Hepatic Differentiation of Human ipscs Disease Modelling with Human ipscs Drug Toxicity and Drug Discovery using Human ipscs Therapeutic Potential of Human ipscs Present Day Utilizations Drug Development and Discoveries Cellular Therapy Toxicology Screening ipsc Cell Lines and ipsc Banks Cancer Research Recent Research & Clinical Updates Building the World s Largest ipsc Repository st Investigator Led Study with ipsc-derived Cell Sheets to Treat Macular Degeneration (RIKEN)... 36

3 World s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for Parkinson s Disease (Kyoto University) Physician Led Study Using ipsc-derived Cell Sheets for Heart Disease (Osaka University)...39 Moving ipsc-derived Platelets Toward the Clinic (CiRA of Kyoto University) Advantages and Disadvantages of ipsc Advantages of ipscs Disadvantages of ipscs Recent Activity: ipsc Research Supply Companies Ncardia and Nanion Technologies FUJFILM Cellular Dynamics and University of California - Irvine Evotec and Celgene Ncardia (Formed by Merger of Pluriomics and Axiogenesis) ID Pharma and Axol Bioscience Evotec and Censo Biotechnologies ORIG3N Fujifilm Establishes CDI Japan Stemgent Company Fujifilm Holdings REPROCELL Recent Activity: ipsc Cell Therapy Companies / Organizations Fate Therapeutics and ONO Pharmaceutical Cynata Therapeutics (Positive Phase I Data) Center for ips Cell Research & Application (CiRA), Kyoto University Osaka University Fujifilm and Takeda Pharmaceutical BlueRock Therapeutics and Universal Cells RIKEN Fujifilm Takes Equity Stake in Cynata Therapeutics Cellular Dynamics International (CDI) RIKEN Centre for Developmental Biology (CDB)... 55

4 MARKET ANALYSIS BY PRODUCT CATEGORY Market Segments Key Findings Introduction Reprogramming Cell Culture Differentiation Cell Analysis Engineering Others MARKET ANALYSIS BY APPLICATION Key Findings Introduction Academic Research Drug Development & Discovery Cellular Therapy Toxicology Screening Stem Cell Banking MARKET ANALYSIS BY GEOGRAPHY Key Findings Introduction North America Europe APAC Rest of the World (ROW) SCIENTIFIC PUBLICATIONS Key Findings Overview of ipsc Research Activity PATENTS Key Findings Introduction Patent List Patents by Geography Commentary

5 Patents by Category Commentary ANALYSIS OF ipsc MARKET LEADERS FEATURED COMPANIES: Companies Specializing in ipsc Products Cellular Dynamics International (CDI), a Fujifilm Company Ncardia REPROCELL Axol Bioscience FEATURED COMPANIES: Broad Providers of Research Tools to Include ipsc Products Lonza Thermo Fisher Scientific Takara Bio FEATURED COMPANIES: Companies Developing ipsc-derived Cell Therapeutics Cynata Therapeutics Fate Therapeutics Megakaryon Corporation RIKEN ORIG3N CONCLUSIONS

6 List of Figures Figure 1: Research Methodology Steps Figure 2: Market Size Estimation Methodology: Bottom-Up Approach Figure 3: Market Size Estimation Methodology: Top-Down Approach Figure 4: Research Design Figure 5: Global Induced Pluripotent Stem Cell Market Estimates (USD billion) Figure 6: Process of ipsc Cell Formation Figure 7: From Somatic Cell to Treatment Figure 8: The Leading Applications for Pluripotent Stem Cell Derivatives Figure 9: ips Derived Models of Diabetic Cardiomyopathy Figure 10: Recent Technological Updates and Clinical Applications of Induced Pluripotent Stem Cells Figure 11: ipsc Technology Figure 12: Human Induced Pluripotent Stem Cell (hipsc)-based Platforms for Drug Development Figure 13: Construction of Carcinogenesis model Figure 14: ipscs in Dentistry Figure 15: Stem Cell Reprogramming Figure 16: Bad effects of ipscs Figure 17: ipsc market Share by Product Type Figure 18: Share of of ipsc Clinical Studies by Region (January 2015 to August 2017) Figure 19: Percentage Share of Patent Granted by Region ( ) Figure 20: Percentage Share of Patents by Categories ( ) List of Tables Table 1: From Innovation to Commercialization Table 2: Global ipsc Market, by Product Category, USD Million, Table 3: Global ipsc Reprogramming Market, by Geography, USD Million, Table 4: Global ipsc Cell Culture Market, by Geography, USD Million, Table 5: Global ipsc Differentiation Market, by Geography, USD Million, Table 6: Global ipsc Cell Analysis Market, by Geography, USD Million, Table 7: Global ipsc Engineering Market, by Geography, USD Million, Table 8: Global ipsc Other Product Category Market, by Geography, USD Million, Table 9: Global ipsc Market, by Application, USD Million, Table 10: Global ipsc Market for Academic Research Application, by Geography, USD Million, Table 11: Global ipsc Market for Drug Development & Discovery Application, by Geography, USD Million, Table 12: Global ipsc Market for Cellular Therapy Application, by Geography, USD Million,

7 Table 13: Global ipsc Market for Toxicology Screening Application, by Geography, USD Million, Table 14: Global ipsc Market for Stem Cell Biobanking, by Geography, USD Million, Table 15: ipsc Publication Output, Growth and Citation Impact, by Country (2008 to 2012) Table 16: Global ipsc Market, by Geography, USD Million, Table 17: North America ipsc Market for Academic Research Application, by Country, USD Million, Table 18: North America ipsc Market, by Product Category, USD Million, Table 19: North America ipsc Market, by Application, USD Million, Table 20: U.S. ipsc Market, by Product Category, USD Million, Table 21: U.S. ipsc Market, by Application, USD Million, Table 22: Europe ipsc Market, by Product Category, USD Million, Table 23: Europe ipsc Market, by Application, USD Million, Table 24: APAC ipsc Market for Academic Research Application, by Country, USD Million, Table 25: APAC ipsc Market, by Product Category, USD Million, Table 26: APAC ipsc Market, by Application, USD Million, Table 27: Japan ipsc Market, by Product Category, USD Million, Table 28: Japan ipsc Market, by Application, USD Million, Table 29: RoW ipsc Market, by Product Category, USD Million, Table 30: RoW ipsc Market, by Application, USD Million,

Recent Progress in ips Cell Research and Application

Recent Progress in ips Cell Research and Application Recent Progress in ips Cell Research and Application Shinya Yamanaka, M.D., Ph.D. Center for ips Cell Research and Application (CiRA), Kyoto University, Japan Takeda - CiRA Joint Program, Shonan, Japan

More information

THE GLOBAL MARKET FOR STEM CELLS

THE GLOBAL MARKET FOR STEM CELLS THE GLOBAL MARKET FOR STEM CELLS BIO035F May 2016 Paul Evers Project Analyst ISBN: 1-62296-292-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA),

More information

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing News Release Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing BlueRock Therapeutics is focused on breakthrough treatments

More information

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1 Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted

More information

A Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited

A Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or

More information

Global Gene Therapy Market Report -2026

Global Gene Therapy Market Report -2026 Global Gene Therapy Market Report -2026 July 2018 Table of Contents 1 Executive Summary 2 Gene Therapy: Overview Viral Vectors for Gene Therapy Viral Vectors Non-Viral Vectors Types of Gene Therapy Somatic

More information

Fujifilm s Initiatives in Regenerative Medicine

Fujifilm s Initiatives in Regenerative Medicine Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business

More information

European Induced Pluripotent Stem Cell Bank

European Induced Pluripotent Stem Cell Bank European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented

More information

Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies

Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager,

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

A Next Generation Stem Cell Company

A Next Generation Stem Cell Company A Next Generation Stem Cell Company Dr. Ross Macdonald, CEO Cynata Therapeutics Limited Proactive Investor Lunch, March 2017 Important Information This presentation has been prepared by Cynata Therapeutics

More information

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US

More information

Innovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium

Innovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes

More information

Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities

Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities Per Morten Sandset p.m.sandset@medisin.uio.no Japan-UiO cooperation within health and care research status and opportunities Japan-UiO cooperation within health and care Brief presentation of the University

More information

The Future of Health Research: It s in Our Culture

The Future of Health Research: It s in Our Culture The Future of Health Research: It s in Our Culture Pop quiz. Who was the inventor of the light bulb? Thomas Edison (1847-1931) If you answered Thomas Alva Edison, you re absolutely wrong. But don t feel

More information

EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE

EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE , 09 MAY 2018 EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE 55% INCREASE IN GROUP REVENUES STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER APTUIT ACQUISITION

More information

Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd.

Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. December 2, 2013 Background March 28, 2013 Capital alliance: DSP took a 1.5billion

More information

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic

More information

Financial Results FY2018 Q3

Financial Results FY2018 Q3 Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs

More information

Realizing the Future that Regenerative Medicine Will Open

Realizing the Future that Regenerative Medicine Will Open 470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine

More information

Regenerative Medicine in Japan

Regenerative Medicine in Japan Cell & Gene Therapy World 2017 Regenerative Medicine in Japan January 19, 2017 Table of Contents Section Title Page # Japanese Regenerative Medicine Market Participants 3 Regenerative Medicine R&D in Japan

More information

For personal use only

For personal use only 10 April 2013 ASX Announcement ECQ: CYNATA INCORPORATED SIGNS FOUNDATION AGREEMENT The Board of Eco Quest advises that its associate company, Cynata Inc, has signed a Foundation License Agreement (FLA)

More information

Stem cells for therapeutic use

Stem cells for therapeutic use Transition to an industrial scale of human stem cell production for therapeutic use by Bruno JARRY, Jean-François STOLTZ and Raymond ARDAILLOU on behalf of a working group joining Academy of Technologies

More information

Proactive Investor Conference Presentation

Proactive Investor Conference Presentation ASX ANNOUNCEMENT 10 March 2017 Proactive Investor Conference Presentation Please find enclosed an Investor Presentation, which Australian stem cell and regenerative medicine company, Cynata Therapeutics

More information

DRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES

DRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES DDin DRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES Exclusive broad R&D collaboration based on Evotec s ipsc platform Mission Develop

More information

Innovating out of Crisis

Innovating out of Crisis Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab

More information

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,

More information

Global Oncology Biosimilars Market

Global Oncology Biosimilars Market Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071

More information

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines

More information

PMDA s Future Activities

PMDA s Future Activities PMDA s Future Activities Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 2017 年 4 月 24 日 18:30 版 Disclaimer The views and opinions expressed in the following

More information

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?

More information

Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017

Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017 Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao 1 29 th November, 2017 Collaboration with Q therapeutics to develop new ipsc therapies for CNS diseases REPROCELL announced a

More information

PMDA s Efforts - Regulation and Innovation. Takao YAMORI, Ph.D. Executive Director Pharmaceuticals and Medical Devices Agency (PMDA)

PMDA s Efforts - Regulation and Innovation. Takao YAMORI, Ph.D. Executive Director Pharmaceuticals and Medical Devices Agency (PMDA) PMDA s Efforts - Regulation and Innovation Takao YAMORI, Ph.D. Executive Director Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint

More information

Business Concepts for Life Scientists: Strategy

Business Concepts for Life Scientists: Strategy Business Concepts for Life cientists: trategy Deb Dauber, PhD, MPH Healthcare Consultant UCF Alum andy Waugh-Ruggles, PhD Founder and Innovator UCF Alum Content Contributors Michael Penn, MD, PhD Anatol

More information

Regulatory Perspectives of Japan

Regulatory Perspectives of Japan International Alliance for Biological Standardization (IABS) Challenge Toward Sound Scientific Regulation of Cell Therapy Products at Kyoto International Conference Center, Kyoto, Japan Regulatory Perspectives

More information

E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015

E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015 E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still

More information

The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017

The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,

More information

APPLICATIONS OF CELL CULTURE MODEL SYSTEM CANCER RESEARCH VIROLOGY TABLE 5 CULTURE MEDIA USED FOR THE PRODUCTION OF

APPLICATIONS OF CELL CULTURE MODEL SYSTEM CANCER RESEARCH VIROLOGY TABLE 5 CULTURE MEDIA USED FOR THE PRODUCTION OF CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED

More information

PENNSYLVANIA. Bioscience Performance Metrics. Pennsylvania Page 1

PENNSYLVANIA. Bioscience Performance Metrics. Pennsylvania Page 1 PENNSYLVANIA Pennsylvania has a leading and specialized bioscience industry. Among the four major subsectors, the State has a specialized employment concentration in two drugs and pharmaceuticals (location

More information

Presidential Commission for the Study of Bioethical Issues 2 nd meeting September

Presidential Commission for the Study of Bioethical Issues 2 nd meeting September Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania

More information

The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic

The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview

More information

MARYLAND. Bioscience Performance Metrics. Maryland Page 1

MARYLAND. Bioscience Performance Metrics. Maryland Page 1 MARYLAND Maryland is home to a specialized and rapidly growing bioscience industry. The State s largest bioscience subsector, research, testing and medical laboratories is also its most specialized in

More information

Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024

Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024 Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024 Pharmaceutical, healthcare, commercial and strategic developments in the Global Pre-Filled Syringes Market 2014-2024 www.gmrdata.com

More information

Holland Innovation Network Team Boston: Walter de Wit Julia Knoeff

Holland Innovation Network Team Boston: Walter de Wit Julia Knoeff Holland Innovation Network Team Boston: Walter de Wit Julia Knoeff Boston and Cambridge in Massachusetts are innovation-focused hubs with world-leading universities such as Harvard, Boston University and

More information

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017 Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market

More information

Global Human Growth Hormones (GH) Drugs Industry. Sizing, Growth and Forecast. Global Human Growth Hormones Deficiency (GHD) Drugs

Global Human Growth Hormones (GH) Drugs Industry. Sizing, Growth and Forecast. Global Human Growth Hormones Deficiency (GHD) Drugs Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Human Growth Hormones (GH) Drugs Industry

More information

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Will Stem Cells Finally Deliver Without Controversy?

Will Stem Cells Finally Deliver Without Controversy? Will Stem Cells Finally Deliver Without Controversy? Keith Gary, Ph.D. Director of Program Development Kansas City Area Life Sciences Institute Olathe North Life Sciences 1 February 2012 What s the Buzz?

More information

Technology Transfer, Academic and Industry Cooperations

Technology Transfer, Academic and Industry Cooperations Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and

More information

The Innovative Medicines Initiative Socio-economic impacts

The Innovative Medicines Initiative Socio-economic impacts The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA

More information

ipsc Models of Congenital Heart Disease Dr James Hudson Group Leader, Organoid Research Lab NHMRC CDF and NHF Future Leaders Fellow

ipsc Models of Congenital Heart Disease Dr James Hudson Group Leader, Organoid Research Lab NHMRC CDF and NHF Future Leaders Fellow ipsc Models of Congenital Heart Disease Dr James Hudson Group Leader, Organoid Research Lab NHMRC CDF and NHF Future Leaders Fellow ipsc for Cardiac Disease Modelling Sharma, Wu & Wu, Stem Cell Research

More information

Is traditional life science venture capital a resource for cell therapy companies yet? Edmond de Rothschild Investment Partners

Is traditional life science venture capital a resource for cell therapy companies yet? Edmond de Rothschild Investment Partners Is traditional life science venture capital a resource for cell therapy companies yet? Gilles NOBÉCOURT Partner, Life Sciences Edmond de Rothschild Investment Partners PRIVATE EQUITY Content 1) Venture

More information

Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan

Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan NIHS Since 1874 Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan October 21, 2013 DISCLAIMER: The views and opinions expressed in

More information

The Life Innovation Policy of Japan and Activities of MEXT

The Life Innovation Policy of Japan and Activities of MEXT The Life Innovation Policy of Japan and Activities of MEXT November 2011 Hiroyuki KAMAI Deputy Director, Life Sciences Division Research Promotion Bureau Ministry of Education, Culture, Sports, Science

More information

significant concerns no or very low predictive power

significant concerns no or very low predictive power Your feedback Citizens concerns should be considered How to ensure ethical concerns are harnessed to drive change? Don t separate Non-animal and animal approaches they are integrated Avoid overstating

More information

Overview and Status Update

Overview and Status Update T H E S C R I P P S R E S E A R C H I N S T I T U T E S C R I P P S F L O R I D A T H E S C R I P P S R E S E A R C H I N S T I T U T E Scripps Florida Overview and Status Update 7 November 2011 Harry

More information

The NYSCF Research Institute

The NYSCF Research Institute Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human

More information

Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been

More information

Education Critical to Stem Cell Therapy Pipeline

Education Critical to Stem Cell Therapy Pipeline June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California

More information

INCJ to make additional investment in Megakaryon

INCJ to make additional investment in Megakaryon News Release INCJ to make additional investment in Megakaryon Tokyo, March 23, 2015 Innovation Network Corporation of Japan ( INCJ ) announced today a decision to make an additional investment of up to

More information

CELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS

CELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS CELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS BIO080B April 2014 Usha Nagavarapu Project Analyst ISBN: 1-56965-794-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Drug Discovery insights. Building

Drug Discovery insights. Building DDin Drug Discovery insights Building Bridges TO ACCELERATE DRUG DISCOVERY The Valley of death Basic Research Applied Research Technology Development & Demonstration Product Commercialization & Market

More information

Professor Martin Pera. University of Melbourne Melbourne

Professor Martin Pera. University of Melbourne Melbourne Professor Martin Pera University of Melbourne Melbourne Human Pluripotent Stem Cells: The Future is Now Martin Pera University of Southern California University of Melbourne Walter and Eliza Hall Institute

More information

Artificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle

Artificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle Volume XX, Issue 60 Artificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle Artificial intelligence (AI) has the potential to transform the pharmaceutical industry.

More information

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges

More information

Centre for NanoHealth

Centre for NanoHealth Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine Unique interdisciplinary R&D environment,

More information

A Next Generation Stem Cell Company. Dr. Ross Macdonald, CEO Cynata Therapeutics Limited September 2017

A Next Generation Stem Cell Company. Dr. Ross Macdonald, CEO Cynata Therapeutics Limited September 2017 A Next Generation Stem Cell Company Dr. Ross Macdonald, CEO Cynata Therapeutics Limited September 2017 Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata

More information

Gene Techno Science Co., Ltd.

Gene Techno Science Co., Ltd. Security Code:4584 Gene Techno Science Co., Ltd. Financial Results for 2Q/FY2018 (Fiscal Year Ending March 2019) November 6, 2018 Cautionary Statement This information material is provided for understanding

More information

Stem Cells: Introduction and Prospects in Regenerative Medicine.

Stem Cells: Introduction and Prospects in Regenerative Medicine. Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,

More information

EVOTEC AG FISCAL YEAR 2017 RESULTS: LEADING EXTERNAL INNOVATION

EVOTEC AG FISCAL YEAR 2017 RESULTS: LEADING EXTERNAL INNOVATION , 28 MARCH 2018 EVOTEC AG FISCAL YEAR 2017 RESULTS: LEADING EXTERNAL INNOVATION 57% INCREASE IN GROUP REVENUES, ADJUSTED GROUP EBITDA UP 60% EXPANSION OF LEADING EXTERNAL INNOVATION PLATFORM INTRODUCTION

More information

Asia-Pacific Next Generation Sequencing (NGS) market by Product - (software and services) by Technology (whole targeted re-sequencing, genome

Asia-Pacific Next Generation Sequencing (NGS) market by Product - (software and services) by Technology (whole targeted re-sequencing, genome Asia-Pacific Next Generation Sequencing (NGS) market by Product - (software and services) by Technology (whole targeted re-sequencing, genome sequencing, de novo sequencing, exome sequencing, RNA-Seq,

More information

Longevity Leaders Conference. February 4, 2019

Longevity Leaders Conference. February 4, 2019 Longevity Leaders Conference February 4, 2019 Forward Looking Statements The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties,

More information

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

More information

Good start for external innovation with new business mix

Good start for external innovation with new business mix Good start for external innovation with new business mix Evotec AG, First Quarter 2018 Results, 09 May 2018 Forward-looking statement Information set forth in this presentation contains forward-looking

More information

Innovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future

Innovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future Innovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future Donald Olds Chief Operating Officer & CFO Aegera Therapeutics Inc. June 8, 2010 1 Discussion Points Why do biotech

More information

Karolinska Institutet - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karolinska Institutet - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karolinska Institutet - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karolinska Institutet - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia

Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion Venture Valuation Independent assessment

More information

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the

More information

Stem Cell Science. Celebrating Two Decades of Progress Toward Clinical Applications MIDDLETON SOCIETY NATIVE AMERICAN HEALTH HOMECOMING REUNIONS

Stem Cell Science. Celebrating Two Decades of Progress Toward Clinical Applications MIDDLETON SOCIETY NATIVE AMERICAN HEALTH HOMECOMING REUNIONS VOLUME 20 NUMBER 4 2018 FOR ALUMNI, FRIENDS, FACULTY AND STUDENTS OF THE UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH Stem Cell Science Celebrating Two Decades of Progress Toward Clinical

More information

RHODE ISLAND. Bioscience Performance Metrics. Rhode Island Page 1

RHODE ISLAND. Bioscience Performance Metrics. Rhode Island Page 1 RHODE ISLAND Rhode Island has a specialized employment concentration in two growing bioscience industry subsectors drugs and pharmaceuticals (location quotient of 1.) and medical devices and equipment

More information

THE STEM CELL DILEMMA

THE STEM CELL DILEMMA THE STEM CELL DILEMMA reprogramming in-house versus off-the-shelf purchase of commerciallyproduced ipsc-derived cell types The case for using more physiologically-relevant cells for modelling disease pathophysiology,

More information

What IMI means for POLAND

What IMI means for POLAND What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)

More information

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and

More information

Global Transfection Technology Market Professional Survey Report 2016

Global Transfection Technology Market Professional Survey Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Transfection Technology Market Professional Survey Report 2016 Global Transfection Technology Market Professional

More information

CONNECTICUT. Bioscience Performance Metrics. Connecticut Page 1

CONNECTICUT. Bioscience Performance Metrics. Connecticut Page 1 CONNECTICUT Connecticut has a specialized and diverse concentration of employment in the overall bioscience industry and in two of its subsectors: drugs and pharmaceuticals (location quotient of 2.01)

More information

BME 177. Engineering stem cells. Gayatri Pal Lecturer Biomolecular Engineering

BME 177. Engineering stem cells. Gayatri Pal Lecturer Biomolecular Engineering BME 177 Engineering stem cells Gayatri Pal Lecturer Biomolecular Engineering Introduction Graduated from MCD Biology (Yeast Cell Cycle) -CIRM classes (Introduction to stem cell biology) Post-doc training

More information

14 May Evotec Q1 2013: Driving Innovation Efficiency

14 May Evotec Q1 2013: Driving Innovation Efficiency 14 May 2013 Evotec Q1 2013: Driving Innovation Efficiency STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY EVOTEC S DRUG DISCOVERY PLATFORM GENERATES GROWTH NEW HORMONE IDENTIFIED

More information

Axol Bioscience SNAPSHOT PRESENTATION ELRIG ADVANCES IN CELL BASED SCREENING Zoe Allen, PhD Product Specialist

Axol Bioscience SNAPSHOT PRESENTATION ELRIG ADVANCES IN CELL BASED SCREENING Zoe Allen, PhD Product Specialist Axol Bioscience SNAPSHOT PRESENTATION ELRIG ADVANCES IN CELL BASED SCREENING 2017 Zoe Allen, PhD Product Specialist z.allen@axolbio.com Overview human cell culture systems induced pluripotent stem cells

More information

VERMONT. Bioscience Performance Metrics. Vermont Page 1

VERMONT. Bioscience Performance Metrics. Vermont Page 1 VERMONT Vermont has developed a specialized employment concentration in medical devices and equipment (location quotient of 1.43). The State s $97 million in academic bioscience research and development

More information

CORPORATE PRESENTATION January 2019

CORPORATE PRESENTATION January 2019 CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current

More information

October 23 & 24, 2018

October 23 & 24, 2018 Tuesday, October 23, 2018 8:30 AM REGISTRATION AND COMPLIMENTARY BREAKFAST 9:00 AM Introduction: Susan L. Solomon, JD The NYSCF Research Institute 9:05 AM Welcome Remarks: Richard Lifton, MD, PhD OPENING

More information

October 23 & 24, 2018

October 23 & 24, 2018 Tuesday, October 23, 2018 8:30 AM REGISTRATION AND COMPLIMENTARY BREAKFAST 9:00 AM Introduction: Susan L. Solomon, JD The NYSCF Research Institute 9:05 AM Welcome Remarks: Richard Lifton, MD, PhD TISSUE

More information

IMMUNOASSAY MARKET. Global Forecast to MarketsandMarkets

IMMUNOASSAY MARKET. Global Forecast to MarketsandMarkets IMMUNOASSAY MARKET [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Application (Infectious Diseases, Cancer, Endocrinology, Cardiology), End-Users (Hospitals,

More information

IR Presentation template [SA, JA, sector]

IR Presentation template [SA, JA, sector] 1 Biotechnology Industry IR Presentation template [SA, JA, sector] Healthcare Sector - Fall 2016 Senior Analyst: Austin Gasparini Junior Analysts: Donavon Young, Marlon Li, Josh Zins Industry Definition

More information

PAUL CLAYDON. Partner and European Head of Pharmaceuticals and Biotechnology Group. May 2001

PAUL CLAYDON. Partner and European Head of Pharmaceuticals and Biotechnology Group. May 2001 PAUL CLAYDON Partner and European Head of Pharmaceuticals and Biotechnology Group May 2001 1 M&A: INDUSTRY TRENDS IN THE LIFE SCIENCES European Biotech Sector European companies using modern biological

More information

EU support for Health Research from FP6 to FP7

EU support for Health Research from FP6 to FP7 EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes

More information

The 3Rs: are Human Stem Cells and Organs on Chip alternatives?

The 3Rs: are Human Stem Cells and Organs on Chip alternatives? The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human

More information

Regenerative Medicine and Stem Cell Therapies

Regenerative Medicine and Stem Cell Therapies Regenerative Medicine and Stem Cell Therapies Regenerative Medicine Major component of successful regenerated / tissue engineered organs Scaffolds A critical element is the binding of the repopulating

More information

De-risking preclinical assets with early human insights recent advances in human tissue and disease models

De-risking preclinical assets with early human insights recent advances in human tissue and disease models De-risking preclinical assets with early human insights recent advances in human tissue and disease models Christopher Boyer, Executive Director, Bio-Link www.bio-link.com 108 South Parade, Blackburn VIC

More information

IOWA. Bioscience Performance Metrics. Iowa Page 1

IOWA. Bioscience Performance Metrics. Iowa Page 1 IOWA Iowa has a highly concentrated and rapidly growing bioscience industry. Iowa has nearly 7 percent of national employment, faster growth than the national average, and a highly specialized concentration

More information